Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Health Care Up, But not by Much, on Cyclical Bias -- Health Care Roundup
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company United Laboratories International, with $200 million up ...
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
Verywell Health on MSN13d
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer Program
Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Health Care Roundup: Market Talk
Gain insight on Centessa Pharmaceuticals, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.
STAT4d
Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say
At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...
PharmExec14h
Halia Therapeutics Wins Novo Nordisk Golden Ticket
Halia won the award for its work with HT-6184, an inflammasome inhibitor that targets inflammation associated with obesity, metabolic dysfunction, and other related diseases.